Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
|
|
10.
|
|
|
11.
|
|
|
12.
|
|
|
13.
|
|
|
14.
|
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. [electronic resource] by
- Price, T J
- Bruhn, M A
- Lee, C K
- Hardingham, J E
- Townsend, A R
- Mann, K P
- Simes, J
- Weickhardt, A
- Wrin, J W
- Wilson, K
- Gebski, V
- Van Hazel, G
- Robinson, B
- Cunningham, D
- Tebbutt, N C
Producer: 20150513
In:
British journal of cancer vol. 112
Availability: No items available.
|